ENSEMBRI
Live / Allowed — Notice of allowance issued (as of 17 Feb 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 07 Nov 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99484398
- Mark type
- Stylized text
- Filed
- 07 Nov 2025
- Published for opposition
- 23 Dec 2025
- Attorney of record
- Cheryl L. Foytlin
Goods and services
- Class 005 — Pharmaceuticals: Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prosecution history
- 17 Feb 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 23 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 Dec 2025 — PUBLISHED FOR OPPOSITION
- 17 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 24 Nov 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 24 Nov 2025 — ASSIGNED TO EXAMINER
- 07 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 07 Nov 2025 — APPLICATION FILING RECEIPT MAILED
- 07 Nov 2025 — NEW APPLICATION ENTERED